A Neurofeedback Intervention to Improve Working Memory in Schizophrenia
Primary Purpose
Schizophrenia
Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Neurofeedback
Sponsored by
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Neurofeedback, Gamma band response
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of schizophrenia/schizoaffective disorder
Exclusion Criteria:
- Active substance use disorders in the last 30 days
- Medication changes in the last 30 days
- History of traumatic brain injury
- seizure disorder
- pregnancy
Sites / Locations
- University of California at San Diego
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Schizophrenia patients
Arm Description
Thirty SCZ patients will receive neurofeedback to enhance gamma band response in an open-label, proof of concept study.
Outcomes
Primary Outcome Measures
Change in Task related Gamma band response (gamma coherence and power)
Gamma-NFBs effects on gamma coherence and gamma power over time will be assessed.
Secondary Outcome Measures
Change in Working memory
Gamma-NFBs effects on non-verbal working memory will be assessed over time.
Full Information
NCT ID
NCT03260257
First Posted
August 17, 2017
Last Updated
September 21, 2023
Sponsor
University of California, San Diego
Collaborators
National Institutes of Health (NIH)
1. Study Identification
Unique Protocol Identification Number
NCT03260257
Brief Title
A Neurofeedback Intervention to Improve Working Memory in Schizophrenia
Official Title
Enhancing Gamma Band Response in Schizophrenia to Improve Working
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 1, 2018 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
December 30, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, San Diego
Collaborators
National Institutes of Health (NIH)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Schizophrenia affects 2.4 million Americans and causes significant individual and societal costs. Cognitive deficits including poor working memory arise early in the course of illness, account for poor long-term outcomes and have been difficult to treat with available treatments. The investigators are proposing to develop a novel, computer-based brain training to improve working memory in schizophrenia patients, which, if successful could have significant personal, societal, and economic impact.
Detailed Description
Schizophrenia (SCZ) is a chronic debilitating mental disorder that affects 2.4 million Americans and leads to considerable individual and societal costs. In patients with SCZ, cognitive deficits (CD) occur early in the course of the illness, are associated with more severe illness, and are the best predictor of functional outcomes. Nonetheless, to date, CD have been difficult to treat using available treatments. Recent studies suggest CD in patients with SCZ may arise from abnormal synchronization of distributed neural networks. Synchronization or synchronous firing of neurons, binds cortical areas into functional networks in a task and state-dependent manner. Thus novel therapies that improve abnormal neural synchrony may improve previously refractory symptoms arising from disordered brain networks.
Neural synchrony or coherence in the gamma band (GBR, 30-45Hz) plays a central role in top-down attention, multisensory processing, perceptual binding and working memory (WM). Patients with SCZ exhibit abnormal GBR, and the magnitude of impairment is associated with the severity of cognitive disorganization. Given these results, improving GBR should improve CD, including WM in SCZ. This hypothesis has been tested and confirmed using repetitive transcranial magnetic stimulation (rTMS). Additionally, EEG-based neurofeedback (NFB) is hypothesized to improve GBR and cognitive function in patients with SCZ. NFB is a low-cost, easily administered and well-tolerated treatment. In healthy controls, Gamma-NFB improves GBR and cognitive function including WM. Thus, the investigators propose testing the feasibility and effectiveness of improving GBR using gamma-NFB in patients with SCZ using the framework of the R61/R33 mechanism.
The first trial (R61) is a proof-of-concept study designed to assess target engagement and dose response curve. Thirty SCZ patients will receive G-NFB training for 12 weeks (2 weekly sessions of 30minute duration) and be assessed for 1) evidence of training, 2) Change in GBR, 3) Change in WM and 4) Change in community functioning. The second trial (R33) aims to confirm target engagement based on training parameters obtained from R61, and to assess whether G-NFB is superior to an active-placebo neurofeedback intervention in improving GBR, WM and community functioning.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
Keywords
Neurofeedback, Gamma band response
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Schizophrenia patients
Arm Type
Experimental
Arm Description
Thirty SCZ patients will receive neurofeedback to enhance gamma band response in an open-label, proof of concept study.
Intervention Type
Other
Intervention Name(s)
Neurofeedback
Intervention Description
Neurofeedback (NFB) will be administered to improve gamma band response. NFBs effects will be measured on gamma coherence and working memory.
Primary Outcome Measure Information:
Title
Change in Task related Gamma band response (gamma coherence and power)
Description
Gamma-NFBs effects on gamma coherence and gamma power over time will be assessed.
Time Frame
This variable will be assessed at t=0, 4 weeks, 8 weeks, 12 weeks and 4 weeks post completion of intervention
Secondary Outcome Measure Information:
Title
Change in Working memory
Description
Gamma-NFBs effects on non-verbal working memory will be assessed over time.
Time Frame
This variable will be assessed at t=0, 12 weeks, and 4 weeks post study completion.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of schizophrenia/schizoaffective disorder
Exclusion Criteria:
Active substance use disorders in the last 30 days
Medication changes in the last 30 days
History of traumatic brain injury
seizure disorder
pregnancy
Facility Information:
Facility Name
University of California at San Diego
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
36085679
Citation
Lin Y, Shu IW, Hsu SH, Pineda JA, Granholm EL, Singh F. Novel EEG-Based Neurofeedback System Targeting Frontal Gamma Activity of Schizophrenia Patients to Improve Working Memory. Annu Int Conf IEEE Eng Med Biol Soc. 2022 Jul;2022:4031-4035. doi: 10.1109/EMBC48229.2022.9870878.
Results Reference
derived
Learn more about this trial
A Neurofeedback Intervention to Improve Working Memory in Schizophrenia
We'll reach out to this number within 24 hrs